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In Brief
Sakellaropoulos et al. designed a
machine learning workflow to predict
drug response and survival of cancer
patients. All pipelines are trained on a
large panel of cancer cell lines and tested
in clinical cohorts. DNN outperforms
other machine learning algorithms by
capturing pathways that link gene
expression with drug response.
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https://doi.org/10.1016/j.celrep.2019.11.017SUMMARY
A major challenge in cancer treatment is predicting
clinical response to anti-cancer drugs on a personal-
ized basis. Using a pharmacogenomics database of
1,001 cancer cell lines, we trained deep neural net-
works for prediction of drug response and assessed
their performance on multiple clinical cohorts. We
demonstrate that deep neural networks outperform
the current state in machine learning frameworks.
We provide a proof of concept for the use of deep
neural network-based frameworks to aid precision
oncology strategies.
INTRODUCTION
Predicting the clinical response to therapeutic agents is a ma-
jor challenge in cancer treatment. To deliver personalizedCell Repor
This is an open access article undtreatment with high efficacy, identifying molecular disease sig-
natures and matching them with the most effective therapeutic
interventions are essential. The advent of the ‘‘omics’’ era has
permitted scientists to dissect the molecular events that are
known to drive carcinogenesis (Alexandrov et al., 2013; Ne-
grini et al., 2010). Nonetheless, effective translation of the
growing wealth of high-throughput profiling data into clinically
meaningful results has been challenging (van’t Veer and Ber-
nards, 2008). The latter is primarily hindered by the lack of reli-
able preclinical models. Although individual cancer cell lines
do not reflect the complexity of clinical cancer tissues with fi-
delity (Weinstein, 2012), when compiled in large panels, they
are able to recapitulate the genomic diversity of human can-
cers (Iorio et al., 2016). These panels can be readily used as
platforms upon which expert systems for the prediction of
pharmacological response may be developed (reviewed in
Vougas et al., 2019). Although, large-scale panels containing
pharmacogenomics data have been made available to the
public domain, well-validated computational algorithms ablets 29, 3367–3373, December 10, 2019 ª 2019 The Author(s). 3367
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Schematic Representation of the
Study Design and Bioinformatics Pipeline
(A) Dataset: the full dataset was compiled using
1,001 cell lines and 251 drugs from the GDSC
database.
(B) Model construction: deep neural networks
(DNNs) were used to predict patient drug response
and compared against two broadly used learning
algorithms: random forest (RF) and elastic net
(Enet) (right panel).
(C) Evaluation: our models were evaluated in
various settings that included the patient drug
response dataset obtained from clinical trials and
TCGA.to accurately predict therapeutic response are still lacking.
Today’s complex omics datasets have appeared too multidi-
mensional to be effectively managed by classical machine
learning algorithms (Libbrecht and Noble, 2015). However,
deep neural networks (DNNs) have the ability to model biolog-
ical complexity and have been effectively applied in various
fields (e.g., image analysis and text mining) with increased
classification accuracy compared with classical computational
methods (Schmidhuber, 2015). DNNs are based on the
modeling of high-level neural networks in flexible, multilayer
systems of connected and interacting neurons, which perform
numerous data abstractions and transformations (LeCun et al.,
2015). In a recent surge of interest, DNNs have been effec-
tively applied in many fields, such as predicting automated
histopathological diagnosis (Coudray et al., 2018). However,
the potential of deep neural networks for predicting response
to cancer therapy needs to be addressed, and studies in this
direction are essential. As shown in Figure S1, its application
in clinical settings is almost absent (Chiu et al., 2019). In this
study, we address this issue by developing a deep neural3368 Cell Reports 29, 3367–3373, December 10, 2019network model to predict pharmacolog-
ical responses using gene expression
data.
RESULTS
A DNN-based workflow was designed to
predict drug responses in cancer patients
using gene expression data, as presented
in Figure 1. In brief, the DNN was trained
and optimized on a 1,001 cell-line drug
response database (Figures 2A–2C), its
performancewas tested blindly on patient
cohorts, and finally it was compared with
state-of-the-art models, i.e., random for-
ests (RFs) (Costello et al., 2014) and
elastic nets (Enets) (Zou and Hastie,
2005) (Figure 1).
We trained our DNN models to predict
drug response from gene expression us-
ing data from the Genomics of Drug
Sensitivity in Cancer (GDSC) database
(Garnett et al., 2012). GDSC comprisesgene expression from 1,001 cancer-cell lines and drug
response data in the form of IC50 values for 251 therapeutic
compounds (Figures 1A, 2B, and 2C; Data S1a, ‘‘Drugs’’). In
particular, we chose to use the open-source DNN framework
provided by H2O.ai (http://www.h2o.ai/), a cluster-read frame-
work, which allows straightforward deployment of our pipeline
to a high-performance computing environment. Then, we eval-
uated and compared DNN to two frequently used learning algo-
rithms: random forest (RF) (Costello et al., 2014) and elastic net
(Enet) (Zou and Hastie, 2005) (Figures 1B and 1C). The perfor-
mance of these models was evaluated with data obtained
from clinical cohorts, including clinical trials, in which gene
expression data were available before treatment with a drug
present in our pharmacogenomics database (Data S1a,
‘‘Drugs’’). We searched the public domain for patient datasets
comprising both gene expression and drug response informa-
tion. Results from a previous study, describing four trials (three
with a single arm and one with multiple ones) suggested that it is
indeed possible to predict clinical drug response using baseline
gene expression levels (Geeleher et al., 2014). However, the
Figure 2. Description of the Dataset Used for Training and Building of the DNN Prediction Framework
(A) Tissue of origin composition of the 1,001 cell lines used as training dataset and platform for generation of our DNN models.
(B) Summary of sources (GDSC: the 1,001 cell lines repository tested on 251 drugs [see C]; CCLP: the same 1,001 cell lines repository examined for expression
levels of 16,445 genes), number of tissue of origin and features analyzed by the machine learning algorithms.
(C) Grouping of all available drugs from the GDSC database according to target pathway, out of which 251 models were trained (for details see also Data S1a –
‘‘Drugs’’).number of patients in all these datasets was very small
(maximum of 5 patients in responders and/or non-responders)
with the exception of bortezomib, a phase II/III clinical trial in pa-
tients with relapsed multiple myeloma (Mulligan et al., 2007). To
more precisely address the question and systematically
compare previous computational approaches to deep learning,
we looked for larger patient datasets with availability of bothgene expression and drug response data. We found such data-
sets on The Cancer Genome Atlas (TCGA) available for two
drugs: cisplatin and paclitaxel (Ding et al., 2016). In addition,
we obtained unpublished gene expression and patient
response data from (1) a clinical trial of a PARP inhibitor, con-
ducted at the MD Anderson Cancer Center, and (2) a cohort
of esophageal adenocarcinomas, treated with neo-adjuvantCell Reports 29, 3367–3373, December 10, 2019 3369
Figure 3. Evaluation of Drug Response
Models on Patient Datasets
(A) Volcano plots of effect size (difference of mean
IC50 between responders and non-responders)
and p values (Wilcox test) of each learning algo-
rithm and percentage of selected genes for each
tested algorithm.
(B) Volcano plots of effect size (mean effect size
per cancer, weighted by number of samples) and
meta-p values (combined using Stouffer’s method
weighted by number of samples) for cisplatin and
paclitaxel after correcting for cancer type.
(C) Boxplot representation and statistical com-
parison using a paired Wilcoxon test of the AUC
values calculated for each learning algorithm,
drug, and gene selection percentage (grouped by
drug).chemotherapy as a clinical model for cisplatin-based therapy
(Lagergren et al., 2017), under the Esophageal Cancer Clinical
and Molecular Stratification (OCCAMS) consortium (Frankell
et al., 2019). All datasets are summarized in Table S1, including
information about the drug name, the total number of patients,
patients in each group (responders versus non-responders), a
short description of each cohort and citation (see also Data
S1a, ‘‘Drugs’’).
To systematically assess the ability of each algorithm to
identify patients that responded or not to each drug, we found
the optimal models for each algorithm using the cell-line data
alone and then applied those optimal models on each clinical
dataset. More specifically, we used 5-fold cross-validation on
the cell-line data to automatically select the optimal hyper-pa-
rameters for each algorithm (Figure 1B; Table S2). Details on
the hyper-parameter space are presented in STAR Methods
(‘‘Hyper-parameter Optimization on Cell Line Data’’). In addition
to the three learning algorithms, we assessed the impact of
feature selection by training each algorithm using all genes as
features or selecting the most highly variable genes. Gene
selection was exclusively performed on the training set to pre-
vent data leak. The optimal models for DNN, RF, and Enet—in
combination with each feature selection approach—were
selected and then retrained on the entire cell-line dataset (Fig-
ure 1B; Data S1h). Finally, these retrained models were applied
on the unseen clinical datasets (Figure 1C). We evaluated each
model by the effect size—measured as the difference in the
mean of predicted IC50 values in the responder versus non-
responder groups—and the associated p values calculated
using the paired Wilcoxon test. The results of our analysis are
summarized as volcano plots for each dataset in (Figure 3).
Overall, deep neural networks perform consistently better
than random forests and elastic nets, both by effect size and
by statistical significance, independent of the percentage of
highly variable genes used in the corresponding models. In
the bortezomib and OCCAMS-cisplatin datasets (Figure 3A),
both DNN and Enet predict that patients who respond to3370 Cell Reports 29, 3367–3373, December 10, 2019the drug have statistically significantly
lower (predicted) IC50 values, as ex-
pected, whereas RF does not yield anysignificant difference in predicted IC50 values between re-
sponders and non-responders. Importantly, DNN performs bet-
ter than Enet in terms of effect size, as measured by the differ-
ence of the mean predicted IC50 value in the non-responder
group compared with the responder group. In the PARP inhib-
itor dataset (Figure 3A), DNN outperforms the other learning al-
gorithms in both metrics, independent of gene selection. In the
TCGA-cisplatin dataset, DNN again outperforms RF and Enet in
both metrics (p value and effect size), independent of the
percentage of genes selected. RF and Enet can barely pass
the significance threshold (p < 0.1), but this depends on the
percentage of selected genes. No algorithm seems to be close
to statistical significance on the paclitaxel dataset with the
exception of the DNN model that uses all genes (p value
of ~0.1). To further investigate this issue, because the TCGA-
cisplatin and paclitaxel datasets include patients with several
cancer types, we tested the performance of the algorithms
separately for each drug and cancer type. We selected the
cancer types with the highest number of patients (at least 40
patients and more than 5 patients in both the responder and
the non-responder groups). This resulted in three cancer
types for TCGA-cisplatin, bladder cancer (BLDCA), cervical
squamous cell carcinoma (CESC), and lung adenocarcinoma
(LUAD), and only one cancer type for paclitaxel, breast cancer
(BRCA). The greater diversity of the paclitaxel dataset may
explain why none of the tested algorithms was able to produce
a statistically significant result in Figure 3A. To adjust for the
cancer-type diversity in these two datasets, we calculated p
values and effect sizes taking into account the cancer type
and the number of patients in each type (see STAR Methods
for details). The results are shown in Figure 3B. In the TCGA-
cisplatin dataset (BLDCA, CESC, and LUAD), we observed an
overall reduction in the p values in all learning algorithms
(because of the smaller sizes of each cancer-type dataset),
and only the DNN models surpassed the statistical significance
threshold. In the paclitaxel dataset (BRCA), DNN models
improved and exceeded statistical significance in the top
Figure 4. Pathway Enrichment Analysis
(A) Schematic representation of pathway enrichment analysis.
(B–D) Heatmap representation of normalized enrichment scores for each significant pathway across the nodes of the first hidden layer of the cisplatin (B),
paclitaxel (C), and bortezomib (D) neural network models, respectively: rows correspond to significant pathways (for each drug), and columns correspond to
nodes of the first hidden layer of each network.80% and 100% selected genes, while the other two algorithms
failed to produce statistically significant results. Finally, we
evaluated the algorithms based on the AUC (area under the
curve). In Figure 3C, we show boxplots of the AUC values—
grouped by learning algorithm—across drugs and gene selec-
tion percentages. We found that DNN models yield statistically
significantly higher AUCs compared with both RF and Enet
models (Wilcoxon paired test). All metrics (effect sizes, p values,
and AUCs with confidence intervals) for each algorithm, gene
selection percentage, and patient dataset are reported in
Data S1b, ‘‘supplementary_clinical.’’
To corroborate our findings, we performed survival analyses
using the predicted IC50 values to split the patients into high-
and low-sensitivity cohorts for every combination of learner
and feature selection scheme (Figure S2). Overall, DNN
performed better than Enet and RF models across drugs, se-
lection, and significance level (Figure S3). In the cases of
bortezomib and cisplatin (TCGA), it achieved significance (p
value less than 0.05) more than the competition, whereas in
the case of the PARP inhibitor, it was the only method to
achieve significance at any selection level (Figures S2A,
S2B, and S2D).
We then asked whether neural networks can learn biologi-
cally meaningful concepts, such as regulatory pathways. To
answer this question, we extracted the weights connecting
the input layer (gene expression) to each of the nodes of the
first hidden layer of the optimal neural network architecture
determined by the nested cross-validation approach for
cisplatin, paclitaxel, and bortezomib. For each drug, we used
the weights to perform pathway enrichment analysis, indepen-
dently for each node of the first hidden layer. The weights of the
first node were not driven by the magnitude of the gene expres-
sion (Table S3). As a control, we retrained the neural network
on randomly permuted IC50 values, performed pathway enrich-ment analysis, and repeated the process 100 times (see STAR
Methods for details). Finally, we kept only the statistically signif-
icantly enriched pathways (bootstrapped p value = 5%, using
the randomly trained networks as control). In Figure 4A, we pro-
vide a schematic of the approach. In Figures 4B–4D (cisplatin,
paclitaxel, and bortezomib, respectively), we show heatmap
representations of the normalized enrichment scores (NESs)
for the significant pathways for each node. We observed that
nodes cluster into subgroups and each subgroup has its own
signature of enriched pathways, suggesting possible connec-
tions between certain pathways and drug mechanisms. To
find evidence linking these pathways to the action of each of
the three drugs, we performed a detailed literature search. Pub-
lication matching was strict, scoring positive only when the sta-
tus of a pathway clearly influenced the drug response. The re-
sults of our analysis (Data S1i–S1k) suggest that the neural
network framework can recognize biological pathways that
dictate the responsiveness of a given drug. For the examined
drugs cisplatin, paclitaxel, and bortezomib, the degree of
confirmation with prior knowledge (literature) was very high:
96%, 79%, and 68%, respectively. As an overall observation,
we noted that although certain pathways were common among
the interrogated drugs, there were also distinct ones that re-
flected their different mode of action. As an example, effective-
ness to cisplatin depended on the status of the DNA damage
response network, drug transporters, and RAS-like signaling
molecules (Damia and Broggini, 2019; Housman et al., 2014;
Galluzzi et al., 2014). In the case of paclitaxel, mechanisms or
factors implicated in microtubule dynamics determine pacli-
taxel responsiveness (Orr et al., 2003; Barbuti and Chen,
2015; Marcus et al., 2005). Lastly, various signaling pathways
affect response to bortezomib, particularly that of nuclear fac-
tor kB (NF-kB), the master regulator of immune response
(Reddy and Czuczman, 2010; Kumar and Rajkumar, 2008).Cell Reports 29, 3367–3373, December 10, 2019 3371
DISCUSSION
Our study presents a clinical validation of cell-line-trained DNN
models topredict drug response fromgeneexpression. It appears
that DNN captures the intricate biological interactionsmore effec-
tively than the current state-of-the-art machine learning frame-
works. Based on our findings, we believe that in the future, thor-
ough molecular profiling of large cell-line collections followed by
drug response assays applied on organotypic cultures (recapitu-
lating tissue architecture) will provide an appealing training plat-
form for delivering DNN-based tools that can eventually become
an integral part of broader precision oncology efforts. To success-
fully pursue this vision, it is clear that a large amount of additional
drug response and genomic data will be necessary to train accu-
rate deep learning models, while extensive evaluation should be
performed on multiple clinical datasets.
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tidyverse_1.2.1LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests should be directed to and will be fulfilled by the Lead Contact, Vassilis G Gorgoulis (vgorg@med.
uoa.gr). This study did not generate new unique reagents.
METHOD DETAILS
All scripting, data-processing, statistical calculations, except RNA-seq analysis, have been performed with R-language for statistical
computing (R Core Team, 2016).
1. Gene expression cell line and patient datasets
Gene Expression of GDSC cell lines
Raw gene expression data for the GDSC cell lines were collected from the Array Express repository (E-MTAB-3610). Drug response
data were obtained from: ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-5.0/gdsc_manova_input_w5.csv. The raw
data was used to train our drug response models after batch correction as described below (‘‘Batch correction between GDSC
cell line data and clinical datasets’’). The Bioconductor Affy package (Gautier et al., 2004) was used to apply Robust Multiarray
Averaging (RMA) normalization to the aforementioned dataset. The normalized gene values can be found in file ‘‘raw/cells.rds’’ avail-
able in the provided link (see Data and Code Availability).
Bortezomib
Raw gene expression data for this clinical trial were not available. Only the pre-processed MAS5 normalized data was publicly
available at GEO:GSE9782. Because concurrent processing of two data-sets with different normalizations (RMA and MAS5) can
be problematic, we proceeded to the analysis as described below (Batch correction between GDSC cell line data and clinical data-
sets). The actual data file, which also contains the clinical response information, was retrieved from (Geeleher et al., 2014).
Cisplatin clinical trial
The pre-processed RMA-normalized gene expression data also containing the clinical response information was retrieved from
(Geeleher et al., 2014).e1 Cell Reports 29, 3367–3373.e1–e4, December 10, 2019
TCGA cisplatin and paclitaxel datasets
These datasets were obtained from the (Frankell et al., 2019).
PARP inhibitor dataset
Note, the name of the inhibitor used in the dataset fromMDAnderson cannot be disclosed as it was applied in the context of a clinical
trial.
OCCAMS dataset
Raw gene expression data from esophageal adenocarcinomas treatedwith three cycles of neoadjuvant cisplatin-based combination
chemotherapy followed by esophagectomy and corresponding histological response and tumor regression grade was obtained from
the International Cancer Genome Consortium (ICGC) dataset through the OCCAMS consortium (Frankell et al., 2019).
Batch correction between GDSC cell line data and clinical datasets
To correct for the batch effect between the raw GDSC cell line and clinical datasets we used the ComBat function of the
SVA Bioconductor package (Leek et al., 2016) with batch, cell lines versus clinical, as the only covariate. DNN, Enet and RF
regression models were trained as described in methods above using training with cross-validation only on the cell line gene
expression data to determine the optimal models for each learning algorithm. The optimal models were utilized to predict
z-score normalized IC50 values for each patient in the clinical dataset from the patient’s gene expression data. The code for normal-
ization is also available in the GitHub page accompanying this publication.
2. RNA-seq analysis
RNA-seq analysis of the OCCAMS clinical samples has been previously described (Frankell et al., 2019), while the MD Anderson
clinical set has been analyzed as follows. RNA was purified and the polyA+ mRNA fraction was used to generate stranded cDNA
libraries according to the following: Quantification of Genomic RNA using Picogreen (Invitrogen, Carlsbad, CA, USA) and quality
assessment using a 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) was performed for each sample. RNA from each sample
(1 mg) was fragmented and converted into double stranded cDNA and then preceded to library prep using TrueSeq RNA Sample
Preparation from Illumina according to the manufacturer protocol. The library prep includes repair ends, A-tailing, Adaptor Indexes
ligation followed by PCR amplification (15 cycles). The PCR primers were removed using 1.8x volume of Agencourt AMPure
PCR Purification kit (Agencourt Bioscience Corporation). At the end of the library prep, samples were analyzed and quantified
on TapeStation (Agilent) using the DNA High Sensitivity kit (Agilent) to verify correct fragment size and to ensure the absence of
extra bands. Equimolar amounts of DNA were pooled for capture (8 samples per pool) and verified by TapeStation. The captured
libraries were sequenced on a HiSeq 4000 (Illumina Inc., San Diego, CA, USA) on a version 3 TruSeq paired end flowcell according
to manufacturer’s instructions at a cluster density between 700 – 1000 K clusters/mm2. Sequencing was performed for 2 3 100
paired end reads with a 7 nt read for indexes using Cycle Sequencing v3 reagents (Illumina). The resulting BCL files containing
the sequence data were converted into ‘‘.fastq.gz’’ files and individual libraries within the samples were demultiplexed using CASAVA
1.8.2 with no mismatches. All regions were covered by > 20 reads.
Raw reads from the RNASeq samples were processed using TopHat 2 for read alignment, FastQC and RSeQC for read and
alignment quality assessment and HTSeq for expression count. The reads were aligned to the hg19 version of the human genome
and mapping to the human transcriptome according to UCSC gene annotations.
3. Prediction of drug response
3.1. Gene selection
Gene selection was performed by selecting the top percentage of highly variable genes in the training set. The median absolute
deviation (MAD) was used to quantify gene variability. Various percentages of highly variable genes were tested to evaluate the
robustness of each algorithm to the number of genes used for modeling drug response.
3.2. Hyper-parameter optimization on cell line data
The hyperparameters for the models were estimated using random grid search and cross-validation on the cell line dataset.
The optimal models were then tested on the patient drug response dataset. In particular, for each learning algorithm, 30 sets of
model parameters were selected at random from the grid and a 5-fold cross validation was performed for every drug and feature
selection strategy. For every split, the most variable genes were extracted and all 30 models were trained and evaluated against
the left-out dataset. The parameters with the lowest average mean-square-error (MSE) across all splits were used to train the
final model on the entire cell line dataset, which was used to predict the patients’ IC50 z-score from the clinical gene expression
data. The grid used is summarized in Table S2. Deep Neural Networks (DNN) and Random Forests (RF) were constructed using
the H2O.ai platform [http://www.h2o.ai/]. Elastic Net models were constructed using the glmnet R package.
3.3. Deep Neural Network Architecture
The basic unit in the model is the neuron, a biologically inspired model of the human neuron. In humans, the varying strengths of
the neurons’ output signals travel along the synaptic junctions and are then aggregated as input for a connected neuron’s
activation. In the model, the weighted combination (a = Sni = 1 wixi + b) of input signals is aggregated, and then an output signal
f(a) transmitted by the connected neuron. The function f represents a nonlinear activation function used throughout the network
and allows it to model non-linear patterns. Multi-layer, feed-forward neural networks consist of many layers of interconnected
neuron units, starting with an input layer to match the feature space, followed by multiple layers of nonlinearity, and ending with aCell Reports 29, 3367–3373.e1–e4, December 10, 2019 e2
classification layer to match the output space. The inputs and outputs of the model’s units follow the basic logic of the single neuron
described above. Bias units are included in each non-output layer of the network. The weights linking neurons and biases with other
neurons fully determine the output of the entire network. Learning occurs when these weights are adapted via backpropagation dur-
ing the training phase to minimize the error on the labeled training data. More specifically, for each training example j, the objective
is to minimize the loss function, L(W, B | j). Here, W is the collection {Wi}1:N1, where Wi denotes the weight matrix connecting layers i
and i + 1 for a network of N layers. Similarly B is the collection {bi}1:N1, where bi denotes the column vector of biases for layer i + 1.
Apart frombackpropagation, modern architectures use a plethora of engineering tricks to fit theweights of a network such as dropout
and batch normalization. For this application, the hyperbolic tangent (tanh) with dropout was used as neuron activation function and
the mean squared error (MSE) as loss function. DNNs have the power to learn feature representations of the sample-space over mul-
tiple levels of abstraction. This capability negates the need for feature selection and engineering, offering at the same time superior
generalisation potential.
3.4. Nested cross-validation
We also performed nested cross-validation on the cell line data in order to estimate the performance of the models exclusively on the
cell line data. In this scenario, the same process and grid were used as described above, but the optimal models (using MSE as a
metric) for each learner and gene selection percentage, were evaluated on the left-out data of the outer 5-fold cross validation split
of the cell line dataset. For each run, we report theMSE, mean-absolute-error (MAE) and the Pearson correlation coefficient between
the predicted and the actual IC50 values.
3.5. Evaluation metrics for drug response in clinical datasets
In all the clinical datasets analyzed (TableS1;DataS1) in the current study except theoneobtained fromMDAnderson, patientswhose
responsewasmarked as Stable Disease (SD) and Progressive Disease (PD) were treated as non-responders, while the oneswith Par-
tial Response (PR) and Complete Response (CR) as responders. For the MD Anderson dataset the clinical Primary Investigator sug-
gested that patients with CR, PR and SD > = 6months should be treated as responders while the ones with SD < 6months and PD as
non-responders. For theOCCAMscohort response to neo-adjuvant cisplatin-based chemotherapywas assessedhistopathologically
in theesophagectomyspecimenandclassifiedaccording toMandardwith TumorRegressionGrade (TRG); TRG1, 2and3considered
to be responders and TRG 4 and 5 considered to be non-responders. The effect size was computed as the mean difference in pre-
dicted IC50 z-scores of responders versus non-responders. The p value was calculated using theWilcoxon rank sum (Mann-Whitney)
test with alternative hypothesis that responders have a higher mean IC50. To adjust for the cancer type diversity in our datasets, we
computed the effect size and p value for each cancer type individually and then merged the result by taking the weighted
average of the effect sizes and using Stouffer’s method (sum of z) for the p values. For this meta-analysis, we only considered cancer
typeswithmore than5patients in eachgroupand40patients in total.Wealsoquantified theability of eachmodel to classify patients as
responders and non-responders using the Area Under the Curve (AUC) calculated on the patients ranked by their predicted IC50
values. The AUC values and confidence intervals were computed using the pROC package (Robin et al., 2011). TheWilcoxon signed
ranked test was used to access the differences between the pairs of training algorithms.
4. Pathway analysis
For the optimal network of each drug, as determined by nested cross-validation, we extracted the weights of the first hidden layer
linking genes from the input layer to the nodes. Using these weights we ran a gene set enrichment analysis (GSEA) (Subramanian
et al., 2005) and calculated the normalized enrichment score of every node against every pathway in Reactome (Fabregat et al.,
2018). To call a drug-pathway score significant, we averaged the enrichment score of the positively and the negatively enriched
nodes for both the original optimal network as well as its bootstrapped versions. The bootstrapped versions were generated
as follows: we permuted the IC50 values of the drug 100 times and reran the training with all the other hyperparameters fixed
(per drug). Then, we calculated a p value for positive/negative enrichment as the number of times the average enrichment score
of the original dataset was higher/lower than the respective bootstrapped versions and adjusted using false discovery rate. We
called an interaction significant if either the positive or negative enrichment p value was less than 0.05. We created one heatmap
per drug: rows represent pathways, columns correspond to nodes of the first layer of the neural network and cells are colored
based on the normalized enrichment score. Pearson correlation distance and the Ward’s method were used to cluster rows
and columns.
QUANTIFICATION AND STATISTICAL ANALYSIS
For every prediction model, we split the patients, based on their predicted IC50, into 3 quantile groups for the TCGA drugs (Bortezo-
mib, Cisplatin, and Paclitaxel) and 2 groups for Cisplatin OCCAMS and PARP inhibitor, since they had far fewer patients. We then
performed Kaplan-Meyer survival analysis to contrast the groups of the lowest and highest IC50. For Paclitaxel, Enet failed to predict
any variance for two feature selection schemes so the corresponding facets are empty. Survival models and p values were calculated
with R’s survival package (v2.44-1.1) and were plotted using survminer (v0.4.6). Models with p value less than 0.05 were considered
significant (table in Figure S3). We also draw the cumulative distribution of all the p value (graph in Figure S3).e3 Cell Reports 29, 3367–3373.e1–e4, December 10, 2019
DATA AND CODE AVAILABILITY
All data files used for training and testing are available via this link: https://genome.med.nyu.edu/public/tsirigoslab/
deep-drug-response/. More specifically, the following files are made available:
d bortezomib_cells.rds: batch-normalized GDSC/bortezomib dataset used for training
d bortezomib_clinical.rds: bortezomib clinical response data
d cisplatin-occams_cells.rds: batch-normalized GDSC/cisplatin (OCCAMS) dataset used for training
d cisplatin-occams_clinical.rds: cisplatin (OCCAMS) clinical response data
d cisplatin_cells.rds: batch-normalized GDSC/cisplatin (TCGA) dataset used for training
d cisplatin_clinical.rd: cisplatin (TCGA) clinical response data
d paclitaxel_cells.rds: batch-normalized GDSC/paclitaxel (TCGA) dataset used for training
d paclitaxel_clinical.rds: paclitaxel (TCGA) clinical response data
d parpi_cells.rds: batch-normalized GDSC/PARP inhibitor dataset used for training
d parpi_clinical.rds: PARP inhibitor clinical response data
The training drug response data before batch-normalization can be found in the ‘‘raw/’’ folder under the same link.
The R code used to normalize, train, test and validate the DNN, RF and Enet models is deposited in GitHub: https://github.com/
TeoSakel/deep-drug-response.
For script parameters, see Data S2.Cell Reports 29, 3367–3373.e1–e4, December 10, 2019 e4
